Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth

Haematologica. 2021 Sep 1;106(9):2507-2510. doi: 10.3324/haematol.2020.276865.

Authors

Renate Burger¹, Anna Otte², Jan Brdon², Matthias Peipp², Martin Gramatzki²

Affiliations

¹ Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel. [email protected].
² Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel.

No abstract available

Publication types

Letter

MeSH terms

Apoptosis
Cell Line, Tumor
Humans
Interleukin-6*
Multiple Myeloma* / drug therapy
Myeloid Cell Leukemia Sequence 1 Protein
Nitriles
Proto-Oncogene Proteins c-bcl-2
Pyrazoles
Pyrimidines
Thiophenes

Substances

Interleukin-6
Myeloid Cell Leukemia Sequence 1 Protein
Nitriles
Proto-Oncogene Proteins c-bcl-2
Pyrazoles
Pyrimidines
S63845
Thiophenes
ruxolitinib